RecombinantMycobacterium bovisBCG is a promising platform to develop vaccines againstTrypansoma cruziinfection
- 1 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 201 (3), 306-316
- https://doi.org/10.1111/cei.13469
Abstract
Chagas disease, caused by the hemoflagelate parasiteTrypanosoma cruzi, is one of the most prevalent endemic parasitoses, affecting 7-8 million people. Due to the complexity of the infection, no vaccines are available at present. The extraordinary adjuvant capacity of bacille Calmette-Guerin (BCG) was explored in this work to develop a vaccine candidate to protect againstT. cruziinfection using the recombinant BCG (rBCG) vaccine platform. Three antigens of the parasite corresponding to the N and C terminal fragments of the enzyme trans-sialidase (NT-TS and CT-TS, respectively) and a fragment of the cruzipain enzyme (CZf) were cloned into the vectors pUS997 and pUS2000 and transformed into the BCG Pasteur strain. In vaccinated mice, rBCG expressing NT-TS in pUS2000 plasmid provided the highest protection and the lowest parasitemia after challenging BALB/c mice with a 50% lethal dose of parasites. When mice vaccinated with pUS2000-NT-TS were challenged with a 100% lethal dose of parasite, high levels of protection were also obtained, together with a low degree of cardiac lesions 120 days after infection. In immunized mice with pUS2000-NT-TS/rBCG clone, the proliferation of CD4(+)cells from splenocytes stimulated with the TS antigen was significant; this stimulation increased interferon (IFN)-gamma and interleukin (IL)-17 within CD4 & x207a; T lymphocytes (LTCD4(+)) cells and IFN-gamma and CD107 expression within LTCD8(+)cells. Therefore, pUS2000-NT-TS/rBCG conferred high levels of protection, which correlated with an immune response orientated towards a T helper type 1 (Th1)/Th17 profile, together with an LTC-specific response, indicating that rBCG is a promising platform to develop vaccines againstT. cruzi.Keywords
Funding Information
- Fondo para la Investigación Científica y Tecnológica (PICT 2015-2544)
- Consejo Nacional de Investigaciones Científicas y Técnicas (BR/13/16)
This publication has 37 references indexed in Scilit:
- Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin AmericaExpert Review of Anti-infective Therapy, 2019
- Experimental Vaccines against Chagas Disease: A Journey through HistoryClinical and Developmental Immunology, 2015
- CD8+ T cells in Trypanosoma cruzi infectionSeminars in Immunopathology, 2015
- Decreased level of antibodies and cardiac involvement in patients with chronic Chagas heart disease vaccinated with BCGMedical Microbiology and Immunology, 2013
- Recombinant Mycobacterium bovis BCGVaccine, 2009
- Trans-Sialidase Recombinant Protein Mixed with CpG Motif-Containing Oligodeoxynucleotide Induces Protective Mucosal and Systemic Trypanosoma cruzi Immunity Involving CD8+ CTL and B Cell-Mediated Cross-PrimingPublished by The American Association of Immunologists ,2007
- Improved outcome of Trypanosoma cruzi infection in rats following treatment in early life with suspensions of heat-killed environmental ActinomycetalesVaccine, 2007
- Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary reportMemórias do Instituto Oswaldo Cruz, 2004
- Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotesVaccine, 2003
- Immunotherapy for leprosy and tuberculosisPublished by Springer Science and Business Media LLC ,1989